Study from 2018 to 2024 on GLP-1 RAs in RA patients; 173 treated, 42 controls. Significant improvements in disease activity, weight loss (4 kg vs 1 kg), pain reduction. 32% of treated patients improved. Discontinuation rates high due to GI effects. Limitations: single-center design and small sample size.
Source: ACR Open Rheumatology
